11 August 2023 in Clinical Therapeutics
20 March 2024 in Pharmacogenomics
Aim: The study aim was to determine caregiver interest and planned utilization of pharmacogenomic (PGx) results for their child with Prader-Willi syndrome. Methods: Caregivers consented to PGx test...
11 August 2025 in Genetics in Medicine Open
Prader-Willi syndrome (PWS) is a complex neurodevelopmental genetic disorder affecting multiple systems. We describe the design and feasibility of a fully remote, patient group-led, genome sequencing (GS) study that will evaluate the impact of genetic variants on the frequency and severity of PWS clinical symptoms, with responsible return of results. A total of 50 participants, or their legally authorized representative, provided consent via videoconference discussion and selected which genetic results would be returned. Participants were sent dried blood spot cards for GS and a buccal swab kit for orthogonal pharmacogenomics analysis. A subset of legally authorized representative LARs participated in semistructured interviews about their GS experience. All 50 participants completed the study and elected to receive their primary findings, and 48 of 49 participants who consented to receive pharmacogenomic information returned the buccal swab kit. Forty-seven participants consented to receive secondary findings per current American College of Medical Genetics guidelines; 2 had actionable results, with online genetic counseling support provided. Three families received medically significant findings related to variants associated with blood clot formation, which is important because individuals with PWS are at an increased risk for thrombotic events. Interview participants expressed a high degree of interest in the findings and emphasized the ease of participating in the study but felt the process was lengthy. A fully remote GS study is feasible to perform within a rare disease population, and responsibly returning genetic findings that are important to families is achievable.
27 February 2026 in JNCI Cancer Spectrum
ECElizabeth Carpenter-Song
+10
Background: Care delivery trials to integrate early palliative care in community oncology practices are needed to enhance guideline-concordant care; however, little is known about how to successfully implement these trials within national research networks. Methods: A process evaluation was conducted to identify and address practice and patient recruitment challenges within a nationwide cluster randomized trial testing 2 implementation strategies (virtual learning collaborative vs technical assistance) for integrating the Educate, Nurture, Advise, Before Life Ends (ENABLE) early palliative care program in the National Cancer Institute Community Oncology Research Program. To examine implementation barriers, we collected quantitative practice and clinician characteristics via surveys and conducted qualitative interviews with clinicians and staff. Interview data were coded and summarized using content analyses to identify barriers to implementing study procedures and the ENABLE program. Results: Surveys and interviews were completed by 33 clinicians, 23 ENABLE coaches, and 19 coordinators in 9 practice clusters between April 2021 and June 2022. Although 78% of practice clusters identified availability of some palliative care services, none routinely referred all newly diagnosed advanced cancer patients to these services as recommended by guidelines. Key research and clinical ENABLE implementation barriers included limited staffing during and after COVID-19, low physician buy-in, belief that ENABLE overlapped with existing palliative services, and participant burden. In response, several trial modifications were made to enhance flexibility with study procedures and the clinical ENABLE intervention. Conclusions: Implementation trials within cancer clinical trial networks must employ pragmatic and iterative study procedures to accommodate clinical practice workflows. Trial Registration: ClinicalTrials.gov Identifier: NCT04062552.